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Abst rac t
Introduction: Bullous pemphigoid (BP) is the most common autoimmune blistering disease. Although pruritus is 
a leading symptom in BP, its specific characteristics have not been explored.
Aim: To determine the itch characteristics in newly diagnosed BP patients by using the Questionnaire of Descriptive 
Assessment of Pruritus and visual analogue scale (VAS) and to correlate itch with disease severity.




Aggravating factors were sweating (50.0%), heat (59.4%) and stress (46.9%), but the major relieving factor was 




important troublesome symptom. Therefore there is a need to search for therapeutic solutions.
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Introduction 
Bullous pemphigoid (BP) is the most common auto-
immune blistering disease characterized by tense blisters 
and urticarial lesions typically localized on the skin in dif-
ferent areas. It has been shown that BP is accompanied 
by pruritus. Moreover, pruritus in BP may precede the 
appearance of blisters and urticarial lesions as the only 
symptom (a prodromal phase) what poses diagnostic 
problems [1–3]. The time period from initial pruritus to 
clinically apparent BP is variable and ranges from several 
weeks to even 10 years [3, 4]. It has also been shown 
that pruritus in patients with autoimmune bullous dis-
eases including BP may negatively impact the quality 
of life (QOL) measured by disease-specific Autoimmune 
Bullous Disease Quality of Life Questionnaire (ABQOL) 
[5]. Furthermore, the issue which consistently yielded 
a negative quality of life in BP was the presence of de-
pression [5]. It is not surprising that the association with 
major depressive disorders has been well documented 
in patients with BP [6, 7]. On the other hand, depression 
or emotional stress is often the result of pruritus, which 
was observed in many patients with atopic dermatitis 
(AD) or psoriasis vulgaris (PV), in which pruritus is a pre-
dominant symptom [8, 9]. 
Although it is generally accepted that patients with 
BP experience pruritus, no detailed analysis and charac-
teristics of itch in BP have been conducted. However, the 
recent study based on the subjective itch numeric scale 
has suggested that pruritus in BP is even as intense as in 
atopic dermatitis [10]. The present study was performed 
to determine the intensity and qualities of pruritus in BP.




The major goal of the study was to determine the itch 
characteristics in BP patients based on the patients’ re-
ported itch questionnaire and itch visual analogue scale 
(VAS), and to correlate it with disease severity measured 
by Bullous Pemphigoid Disease Area Index (BPDAI) [2]. 
Material and methods  
The study included 32 with BP (mean age: 75.4 ±12.2 
years, range: 40–100; 20 women, 12 men). Patients were 
recruited from 2013 to 2014. The diagnosis in BP was de-
termined based on direct immunofluorescence (DIF) which 
showed IgG and C3 deposits along the basement mem-
brane zone (BMZ), and indirect immunofluorescence (IIF) 
which revealed circulating IgG anti-BMZ antibodies. In all 
BP cases, circulating antibodies reacted with BP 180 NC16a 
domain in the commercial ELISA kit Mesacup BP180 Test 
(MBL Co., Nagoya, Japan). The patients with BP were new-
ly-diagnosed, referred to the department to establish the 
diagnosis of BP. During the study the presence of any other 
concurrent skin disease that may also cause pruritus such 
as renal or liver impairment and other acute or chronic 
diseases was the exclusion criterion. The disease sever-
ity was measured by BPDAI. All patients were requested 
to complete the Questionnaire of Descriptive Assessment 
of Pruritus authored by Szepietowski and Reich (2010) 
[11]. The questionnaire consists of 12 questions regarding 
the details of pruritus such as duration of itch episodes 
(< or > than 10 min), occurrence at different times of the 
day, aggravating and relieving factors, taking anti-pruritic 
medications, sleep disturbances caused by itch and tak-
ing sleeping medications, effect of pruritus on quality of 
life. The intensity of itch was assessed by itch VAS in all 
patients. Based on literature data, the following interpreta-
tion criteria were used: 0 = no itch, 1 – < 4 points = mild 
itch, ≥ 4 – < 7 points = moderate itch, ≥ 7 – < 9 points = 
severe itch, and ≥ 9 points = very severe itch [12]. Consent 
of the Bioethics Committee of the Medical University of 
Warsaw was obtained prior to the study. All patients gave 
their informed consent to participate in the study.
Statistical analysis 
Statistical analyses were performed using statistical 
software package SAS Enterprise Guide 7.1. Variables 
with a normal distribution are presented as means fol-
lowed by standard deviation (SD) with range values. Cor-
relations of itch intensity with the extent of disease were 
evaluated by Spearman correlation coefficients. Value of 
p < 0.05 was considered significant. 
Results 
The mean result of BPDAI was 56.5 ±36.2 (range: 
3–148). Pruritus occurring at least once a day was re-
ported in 78.1% (25/32) of BP patients. The presence of 
pruritus “within the last 3 days” was declared by 93.8% 
(30/32) of BP patients. Pruritus tended to persist for more 
than 10 min (long itch episodes) in 56.3% of responders 
(18/32). Antipruritic treatment was used in 53.1% (17/32) 
of BP patients (Table 1). Patients with BP reported pruri-
tus more frequently in the evening (72% of subjects) and 
at night (62% of subjects) (Table 2). Pruritus aggravating 
factors in BP patients involved sweating (in 50.0% of pa-
tients), heat (in 59.4%) and stress (in 46.9%) (Figure 1). 
However, BP patients did not observe that physical activi-
ties, food and dryness affected pruritus. Pruritus was re-
lieved by cold (34.4%). The intensity of itch in BP patients 
expressed by the mean VAS score was 5.8 ±2.7 (range: 
0–10) points. The result above 7 points in VAS (denoting 
at least severe itch) was reported by 22.6% of patients 
with BP. The VAS score did not correlate with BPDAI (r = 
–0.04, p = 0.83).
Patients declared that itching disturbed falling asleep 
(53.1% of respondents) (Table 3). Patients were awake 
at night because of pruritus in 50% of cases. However, 
sleeping medications were not used much in BP patients. 
Patients felt depressed in 59.4% and reported difficulty in 
concentrating in 31.3% because of pruritus. 
Discussion
Despite a great variability of clinical BP manifestations, 
pruritus represents the leading clinical symptom. To the 
best of our knowledge, we are presenting the first char-
acteristics of itch in newly diagnosed BP patients based 
on the itch questionnaire. The study confirmed the clinical 
observation that pruritus in BP is one of extremely trouble-
some symptoms to patients. We showed that almost 80% 
of patients with BP declared pruritus at least once a day 
whereas more than 90% reported pruritus over the previ-
ous 3 days. The comparison to literature data obtained in 
patients with other pruritic diseases such as AD and PV 
showed that the frequency of daily pruritus in BP patients 
was between AD and PV. Such declaration was observed 
in 83–91% of AD respondents and in 60–90% of patients 
with psoriasis [8, 13–19]. In the research conducted by 
O’Neill et al., the comparison between AD and PV showed 
more frequent and more intense itch in patients with AD 
than in patients with PV [20]. 
In our study, patients with BP presented with pruritus 
of moderate intensity according to the interpretation of 
the VAS score. These findings support the data of the 
recently published study in BP, however the intensity of 
pruritus in the BP group was assessed as severe, rated 
at 7.7 in the numeric rating scale (a variant of VAS) [10]. 
Of note, in the literature, the average itch intensity in AD 
was noted as moderate, severe or very severe whereas 
in PV mainly as moderate itch [8, 14, 15, 17, 19]. It also 
points that pruritus in BP is less intense than in AD and 
more intense than in PV.
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During analysis of the relationship between the in-
tensity of pruritus in BP and the extent of skin lesions 
measured by BPDAI no correlations between the anal-
ysed parameters were observed. The same results were 
presented by Kulczycka-Siennicka et al. who studied the 
group of 28 patients with BP [10]. Thus, our and the previ-
ous study indicate that pruritus in BP is an independent 
symptom from disease severity. However, more studies 
are required to confirm this observation.
It is interesting to note that more than half of BP pa-
tients had long-term episodes of pruritus (lasting longer 
than 10 min). The majority of surveyed BP patients in the 
current study reported pruritus in the evening and at night 
while it was much reduced in the morning when patients 
were rested. Such sensation of more frequent itch in the 
evening and at night was reported in patients with AD 
in the previous studies [8, 13, 14]. The explanation of the 
above-mentioned observation may be the assertion that 
pruritus often appears due to tiredness in the evening 
and/or decreased pruritus threshold in the warmth in bed. 
Additionally, it is suggested that during the evening rest, 
patients become more aware of pruritic feelings compared 
to other day times when they are more active [14]. 




n = 32 (%)
Daily occurrence of pruritus 25 (78.1%)
Occurrence of pruritus over the previous 3 days 30 (93.8%)
Duration of pruritus episodes > 10 min 18 (56.3%)
Antipruritic treatment 17 (53.1%)
Table 2. Prevalence of pruritus depending on the time  
of the day in patients with bullous pemphigoid
Answers Time of the day
Morning Afternoon Evening Night
All time 7 (21.9%) 8 (25.0%) 11 (34.4%) 12 (37.5%)
Often 7 (21.9%) 6 (18.8%) 12 (37.5%) 8 (25.0%)
Seldom 13 (40.6%) 14 (43.8%) 7 (21.9%) 7 (21.9%)































































Almost always 17 (53.1%) 16 (50.0%) 5 (16.6%)
Seldom 4 (12.5%) 6 (18.8%) 8 (25.0%)
Never 11 (34.4%) 10 (31.3%) 19 (59.4%)
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The prevalence of pruritus during evening and night 
periods should also not be surprising as many patients 
with itchy diseases often complain about sleep distur-
bances. In our study, the majority of patients with BP 
declared that itching impaired their ability to fall asleep 
and caused awakening from sleep. These findings seem 
to be underdiagnosed in clinical practice in BP patients. 
It seems that patients with BP have a higher risk of prob-
lems with falling asleep than patients with AD and PV. It 
was estimated in the literature that 42–84% responders 
with AD and about 70% patients with psoriasis had prob-
lems with falling asleep [8, 9, 14, 15]. 
In the present study, majority of BP patients consid-
ered pruritus as a factor contributing to depression. Of 
note, bullous pemphigoid is an itching disease but the 
association with major depressive disorders has also 
been documented recently [6, 7]. On the other hand, it 
should be remembered that patients with BP are elderly 
and the depression observed in these patients may result 
from age and other related factors, such as loneliness. 
Many factors influence the frequency and intensity 
of pruritus [8, 14, 15, 19]. In the present study, sweating 
(50.0%), heat (59.4%) and stress (46.9%) were the three 
most important exacerbating factors in the group of BP 
patients. Interestingly, there was no clear aggravation 
due to skin dryness, food, physical activities and hot wa-
ter. Pruritus in BP was not clearly reduced by any of the 
assessed factors except for cold.
The exact pathogenesis of pruritus in BP remains un-
known. However, it is suggested that pruritus in BP may 
be linked to the autoimmune response initiated by loss 
of self-tolerance against cutaneous autoantigens result-
ing in the induction of IgG autoantibodies [21]. In fact, 
70–96% of all BP sera contain IgG autoantibodies against 
BP180 NC16A and their levels correlate with disease ac-
tivity [21]. Interestingly, some studies disclosed the posi-
tive correlation between serum levels of IgG BP180 and 
BP230 antibodies and intensity of pruritus in BP patients 
suggesting the role of BP180 as a tool of pruritus evalu-
ation in BP [22, 23]. In addition, recent studies showed 
that IgG autoantibodies to BP180 and BP230 were also 
detected in patients with various pruritic disorders who 
did not yet fulfil all the diagnostic criteria of BP [3, 24]. In 
these individuals, tissue-bound IgG antibodies were not 
detected at the epidermal basement membrane. Such 
patients are suggested to represent a pre-disease state 
of BP. It is also suggested that itching might lead to the 
release of a mixture of intracellular BP230 and extracel-
lular components of BP180. Additionally, IgG BP230 au-
toantibodies are able to induce pro-inflammatory effects 
such as granulocyte influx triggering pruritus induction 
followed by the development of anti-BP180 IgG which is 
named epitope spreading [25]. Concomitant induction of 
anti-BP180 and anti-BP230 IgG may directly cause itch as 
a prodromal symptom of BP. 
While IgG autoantibodies clearly dominate the au-
toimmune response in BP, it seems that IgE antibodies 
might also play a crucial role in the explanation of patho-
logical mechanisms of itchiness in BP [26]. It was showed 
that IgE antibodies specific for BP180 or BP230 have been 
detected in clinically active BP [27]. Additionally, it has 
been shown that the presence of pathogenic BP IgE an-
tibodies contribute to separate the dermal–epidermal 
adhesion in experimental animal models. Fairley et al. 
showed that injection of circulating anti-NC16a IgE into 
a human graft on mice reproduced urticarial lesions [26]. 
It is hypothesized that circulating and tissue-bound IgE 
autoantibodies play a role in the initial phases of BP such 
as urticarial lesions. 
The limitation of this study is the small sample repre-
sentation of BP patients resulting from the evaluation by 
a single university centre. We believe that our results are 
important because there are no data on the clinical mani-
festation of pruritus symptoms in bullous pemphigoid.
Conclusions 
Our study confirms that pruritus is one of the main 
disturbing symptoms in patients with BP. Physicians 
should be aware of high frequency, intensity and nature 
of pruritus in BP. Identification of characteristic sensa-
tions associated with pruritus in BP should be included 
in the therapeutic process of BP patients. On the basis 
of our experience and study results we would like to rec-
ommend introducing antihistaminic drugs in patients 
with BP and associated pruritus. It is also significant to 
educate patients about hygiene procedures and the ne-
cessity to avoid factors which may exacerbate pruritus.
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